Comparative Pharmacology
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus MYDAYIS.
DEXMETHYLPHENIDATE HYDROCHLORIDE vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug)
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category A/B
Category C
CNS Stimulant
CNS Stimulant